Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] Jeju Semiconductor(080220) – Results of Extraordinary General Meeting of Shareholders / 2026-07-30

Posted on July 30, 2026August 3, 2026 By K-STOCK Editor No Comments on [Disclosure] Jeju Semiconductor(080220) – Results of Extraordinary General Meeting of Shareholders / 2026-07-30

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Jeju Semiconductor held an Extraordinary General Meeting of Shareholders where most agenda items, including amendments to the articles of incorporation following commercial law revisions and approval of director compensation limits, were approved, while the proposal to amend articles regarding class share issuance was rejected.

📊 [Key Disclosure Contents & Summary of Major Figures]

  1. Meeting Overview
  • Record Date for Voting Rights: 2026-05-27
  • Date of Shareholders’ Meeting: 2026-07-30
  • Disclosure Category: Results of Extraordinary General Meeting of Shareholders
  1. Detailed Results by Agenda Item
  • Agenda Item 1-1 (Special Resolution): Amendment to Articles of Incorporation (Reflecting Commercial Act Revisions) · Outcome: Approved · Voting Shares Base: Approved 94.0% / Opposed, Abstained, etc. 6.0% · Outstanding Voting Shares Base: Approved 38.5%
  • Agenda Item 1-2 (Special Resolution): Amendment to Articles of Incorporation (Changes to Class Share Issuance Provisions) · Outcome: Rejected · Voting Shares Base: Approved 70.3% / Opposed, Abstained, etc. 29.7% · Outstanding Voting Shares Base: Approved 28.8%
  • Agenda Item 1-3 (Special Resolution): Amendment to Articles of Incorporation (Changes to Equity-linked Securities Provisions) · Outcome: Approved · Voting Shares Base: Approved 93.7% / Opposed, Abstained, etc. 6.3% · Outstanding Voting Shares Base: Approved 38.4%
  • Agenda Item 1-4 (Special Resolution): Amendment to Articles of Incorporation (Changes to Electronic Securities & Standard Corporate Provisions) · Outcome: Approved · Voting Shares Base: Approved 98.2% / Opposed, Abstained, etc. 1.8% · Outstanding Voting Shares Base: Approved 40.2%
  • Agenda Item 1-5 (Special Resolution): Amendment to Articles of Incorporation (Other Textual Changes) · Outcome: Approved · Voting Shares Base: Approved 98.0% / Opposed, Abstained, etc. 2.0% · Outstanding Voting Shares Base: Approved 40.1%
  • Agenda Item 2 (Ordinary Resolution): Approval of Fixed Compensation Limit for Directors · Outcome: Approved (Approved as original draft) · Voting Shares Base: Approved 96.6% / Opposed, Abstained, etc. 3.4% · Outstanding Voting Shares Base: Approved 31.9% · Remarks: Voting rights restricted for specially interested parties pursuant to Article 368, Paragraph 3 of the Commercial Act
  • Agenda Item 3 (Ordinary Resolution): Approval of Performance-based Compensation Limit for Directors · Outcome: Approved (Approved as original draft) · Voting Shares Base: Approved 96.8% / Opposed, Abstained, etc. 3.2% · Outstanding Voting Shares Base: Approved 31.9% · Remarks: Voting rights restricted for specially interested parties pursuant to Article 368, Paragraph 3 of the Commercial Act
  • Agenda Item 4 (Ordinary Resolution): Approval of Treasury Stock Holding and Disposition Plan · Outcome: Approved · Voting Shares Base: Approved 98.2% / Opposed, Abstained, etc. 1.8% · Outstanding Voting Shares Base: Approved 40.2%

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of Extraordinary General Meeting Voting Outcomes

At this Extraordinary General Meeting of Shareholders, final voting outcomes were determined for submitted agenda items regarding articles of incorporation amendments, director compensation limits, and treasury stock plans, with the proposal on class share issuance provisions (Item 1-2) being rejected. Checking the actual approval or rejection status and vote tallies for each proposal is important to determine whether the meeting outcomes have been officially reflected in the company’s articles and governance decisions. Final changes and updated corporate details can be verified in subsequent periodic disclosures (Quarterly/Half-Yearly/Annual Reports) or follow-up regulatory filings.

📢 Disclaimer and Source Notice

Fact Source: Financial Supervisory Service DART

Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Semiconductors

Post navigation

Previous Post: [Disclosure] Samsung Electro-Mechanics (009150) – Consolidated Earnings Announcement (Provisional) / 2026-07-30
Next Post: [Disclosure] Celltrion (068270) – CT-P55 (Cosentyx Biosimilar) U.S. BLA Submission / 2026-07-30

Related Posts

[Disclosure] Celltrion (068270) – Treasury Share Acquisition Decision / 2025-04-28 Disclosures
[Disclosure] ALTEOGEN (196170) – Additional Listing (Exercise of Stock Options) / 2024-10-24 Disclosures
[Disclosure] SK hynix (000660) – Investor Relations (IR) Holding (Information Disclosure) / 2025-07-09 Semiconductors
[Disclosure] Jeju Semiconductor (080220) – Securities Issuance Results (Voluntary Disclosure) / 2026-04-10 Semiconductors
[Disclosure] Celltrion (068270) – Provisional Earnings Release (Consolidated Basis) / 2026-02-05 Disclosures
[Disclosure] Samsung Electronics (005930) – (Correction) Provisional Consolidated Financial Performance (Fair Disclosure) / 2024-04-30 Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme